Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+)-(E)-7-[4-[4-[[[2-(trans)-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000085 mM, 50% inhibition
(+)-5-(2-imidazole-1-ethyloxy)-1-indan-carboxylic acid
-
trivial name camonagrel
(+/-)-6-(1-Imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid hydrochloride hemihydrate
-
improvement of the renal function with the selective thromboxane A2 synthetase inhibitor
(-)-(E)-7-[4-[4-[[[2-(trans)-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000059 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3,3-dimethyl)guanidinophenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000026 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(1-adamantyl)-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000003 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(2-dimethylaminoethyl)-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.0029 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(2-methylpropyl)guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000025 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(3-methylbutyl)guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000003 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(3-pyridylmethyl)-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000032 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-benzylguanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000011 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-cyclohexyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000003 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-cyclopentyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000003 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-cyclopropyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.00038 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-isopropyl)guanidinophenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000024 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-methyl)guanidinophenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.00025 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-tert-butyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000004 mM, 50% inhibition
(5E)-6-(4-(2-cyano-3-cyclopentyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.00018 mM, 50% inhibition
(5E)-6-(4-(2-cyano-3-cyclopropyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.0039 mM, 50% inhibition
(5Z)-6-[(2S,4R)-4-(4-Chlorophenylsulphonylamino)-1-(3-pyridylmethyl)-2-pyrrolidinyl]-5-hexenoic acid hydrochloride
-
thromboxane A2 synthetase inhibitor/thromboxane A2-receptor antagonist
(E)-6-[4-(3-tert-butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)hex-5-enoic acid
-
trivial name terbogrel
(E)-7-[4-[4-[(benzylamino)carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000025 mM, 50% inhibition
(E)-7-[4-[4-[(pentylamino)carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridiyl)hept-6-enoic acid
-
0.000031 mM, 50% inhibition
(E)-7-[4-[4-[(phenylethylamino)carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000094 mM, 50% inhibition
(E)-7-[4-[4-[[(2-phenoxybutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000049 mM, 50% inhibition
(E)-7-[4-[4-[[(2-phenoxyethyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000026 mM, 50% inhibition
(E)-7-[4-[4-[[(2-phenoxypentyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000049 mM, 50% inhibition
(E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000055 mM, 50% inhibition
(E)-7-[4-[4-[[(4-cyclopropylmethyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000025 mM, 50% inhibition
(E)-7-[4-[4-[[3-(morpholinopropyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000051 mM, 50% inhibition
(E)-7-[4-[4-[[[2-(benzyloxy)ethyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000048 mM, 50% inhibition
(E)-7-[4-[4-[[[2-(cyclohexylmethoxy)ethyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000037 mM, 50% inhibition
(E)-7-[4-[4-[[[2-(cyclohexyloxy)ethyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000033 mM, 50% inhibition
(E)-7-[4-[4-[[[2-(tetrahydropyran-2-ylmethoxy)ethyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000063 mM, 50% inhibition
(E)-7-[4-[4-[[[3-(1-cyclohexylethoxy)propyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000012 mM, 50% inhibition
(E)-7-[4-[4-[[[3-(4-methoxyphenyl)propyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000027 mM, 50% inhibition
(E)-7-[4-[4-[[[3-(cyclohexyloxy)propyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000042 mM, 50% inhibition
(E)-7-[4-[4-[[[3-[(cis)-4-methoxycyclohexyl]propyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000029 mM, 50% inhibition
(E)-7-[4-[4-[[[4-(cyclohexyloxy)butyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000049 mM, 50% inhibition
1(omega-Carboxylalkyl)imidazoles
-
very potent
-
1-(2-Isopropylphenyl)-imidazole
-
strong
1-Decylimidazole
-
strong
1-Nonylimidazole
-
strong
1-[2-(4,5,6,7-tetrahydrobenzo[b]furan-4-yl)ethyl]-1H-imidazole
-
0.001 mM, 50% inhibition
1-[2-(4,5,6,7-tetrahydrobenzo[b]furan-4-ylidene)ethyl]-1H-imidazole
-
E isomer, 0.00355 mM, 50% inhibition; Z isomer, 0.0041 mM, 50% inhibition
1-[2-(4,5,6,7-tetrahydrobenzo[b]thiophen-4-yl)ethyl]-1H-imidazole
-
0.0012 mM, 50% inhibition
1-[2-(4,5,6,7-tetrahydrobenzo[b]thiophen-4-ylidene)ethyl]-1H-imidazole
-
E isomer, 0.0017 mM, 50% inhibition; Z isomer, 0.0013 mM, 50% inhibition
1-[2-(benzo[b]thiophen-4-yl)ethyl]-1H-imidazole
-
0.0053 mM, 50% inhibition
12L-Hydroperoxy-5,8,10,14-eicosatetraenoic acid
-
0.1 mM, 50% inhibition
1H-Imidazol-1-ylalyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives
-
dual thromboxane synthase inhibitor/thromboxane receptor antagonists
2-Isopropyl-3-nicotinylindole
2-[4-Carboxy-8-(5-imidazol[1,5-a]pyridinyl)octanoyl]-2,3-dihydro-1H-1-isoindole-1-carboxylic acid
-
-
2-[[1-(Carboxymethyl)-2,3,4,5,-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]-6-[[5-[5-chloro-1-methyl-2-(3-pyridinyl)-1H-indol-3-yl]pentanoyl]amino]hexanoic acid
-
-
2-[[1-(Carboxymethyl)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]6-[[5-[5-chloro-1-methyl-2-(3-pyridinyl)-1H-indol-3-yl]pentanoyl](2-hydroxyethyl)amino]hexanoic acid
-
-
2-[[1-(Carboxymethyl)-2,3,4,5-tetrahydro-2-oxo-1H-benzazepin-3-yl]amino]-6-[[1-[5-[5-chloro-1-methyl-2-(3-pyridinyl)1H-indol-3-yl]pentanoyl]piperidin-4-yl]amino]hexanoic acid
-
-
2-[[1-(Carboxymethyl)-2,3,4,5-tetrahydro-2-oxo-1H-benzazepin-3-yl]amino]-6-[[5-[5-chloro-1-methyl-2-(3-pyridinyl)1H-indol-3-yl]pentanoyl][2-(methylamino)ethyl]amino]hexanoic acid
-
-
2-[[1-(Carboxymethyl)-2,3,4,5-tetrahydro-2-oxo-1H-benzazepin-3-yl]amino]-7-[[2-[[5-[5-chloro-1-methyl-2-(3-pyridinyl)1H-indol-3-yl]pentanoyl]amino]ethyl]amino]heptanoic acid
-
-
3-Pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives
-
dual thromboxane synthase inhibitor/thromboxane receptor antagonists
4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)imidazole
-
trivial name SB203580
4-(Benzylamino)-2-(3'-pyridyl)quinazoline
-
-
4-(Benzylamino)-2-(imidazol-1-yl)-quinazoline
-
-
4-{2-[(4-chlorophenyl)methyl]-3-phenylpropanoyl}phenyl hydrogen benzylphosphonate
5-[2-(imidazol-1-yl)-ethyl]-5,6,7,8-tetrahydroquinoline
-
0.00063 mM, 50% inhibition
5-[2-(imidazol-1-yl)ethyl]-1,2,3,4-tetrahydronaphthalene
-
0.0034 mM, 50% inhibition
5-[2-(imidazol-1-yl)ethyl]-7,8-dihydroquinoline
-
0.00029 mM, 50% inhibition
5-[2-(imidazol-1-yl)ethyl]quinoline
-
0.0012 mM, 50% inhibition
5-[3-(imidazol-1-yl)-propyl]-5,6,7,8-tetrahydroquinoline
-
0.0023 mM, 50% inhibition
5-[3-(imidazol-1-yl)-propyl]-7,8-dihydroquinoline
-
0.00068 mM, 50% inhibition
5-[imidazol-1-yl-methyl]-5,6,7,8-tetrahydroquinoline
-
0.002 mM, 50% inhibition
5-[imidazol-1-yl-methyl]-7,8-dihydroquinoline
-
0.0015 mM, 50% inhibition
5E-6-(3-cyanoguanidino)phenyl-6-(3-pyridyl)hex-5-enoic acid
-
0.00043 mM, 50% inhibition
7-[(imidazol-1-yl)methyl]isoquinoline
-
0.0054 mM, 50% inhibition
8-[2-(3-Pyridinyl)-1H-indol-1-yl]octanoic acid 1-(carboxymethyl)-3-[(1-carboxy-3-phenylpropyl)amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-5-yl ester
-
-
9,11(Epoxymethano) prostanoic acid
-
-
9,11-Azo-15-hydroxyprosta-5,13-dienoic acid
-
-
9,11-Azoprosta-5,13 dienoic acid
-
-
9,11-Azoprosta-5,13-dienoic acid
-
-
9,11-Epoxymethano-15-hydroxy-prosta-5,13-dienoic acid
-
-
9alpha,11alpha-Azo-15-(S)Hydroxyprosta-5(cis)-13(trans)-dienoic acid
-
-
9alpha,11alpha-Methanoepoxy-15(S)-hydroxyprosta-5(cis)-13(trans)-dienoic acid
BM 567
-
i.e. 2-(cyclohexylamino)-5-nitro-N-[(pentylamino)carbonyl]-benzenesulfonamide, 10 microM, a specific inhibitor for thromboxane synthase, decrease the acitivity 2.1fold before diosgenin treatment
carboxyheptyl imidazole
-
10 microM, concentration of thromboxane B2 in culture supernatants: reduction of thromboxane B2 in prostate cancer cells PC-3 from 1295 pg/ml to 685 pg/ml, reduction of thromboxane B2 in erythroleukemia cells HEL from 580 pg/ml to 292 pg/ml. In PC-3 cell lysates reduction of thromboxane B2 level by 86%
Chlorella powder
-
the potent inhibition of cyclooxygenase-2 and thromboxane synthase contribute to the purported anti-inflmammatory and anti-thrombotic effect of Chlorella. This might be exploited for the prevention or treatment of several serious pathologies, including inflammatory diseases, immune and cancer
-
clotrimazole
-
as a heme ligand, molecular dynamics simulations of clotrimazole and 2-p-toluidinylnaphthalene-6-sulfonic acid-docking enzyme
CV4151
-
0.0000049 mM, 50% inhibition
-
indomethacin
-
0.000017 mM, 50% inhibition of PGE2 formation, 0.000013 mM, 50% inhibition of 12-HHT formation
linoleic acid
-
significant inhibition of cyclooxygenase/thromboxane synthase activity, determined by TXB2 production with an ELISA-based assay
linolelaidic acid
-
significant inhibition of cyclooxygenase/thromboxane synthase activity, determined by TXB2 production with an ELISA-based assay
N-isopropyl-N'-[(2-(3'-methylphenylamino)-5-nitrobenzene)sulfonyl]urea
-
-
N-isopropyl-N'-[2-(3'-methylphenylamino)-5-nitrobenzenesulfonyl]urea
-
0.001 mM, 95% inhibition
N-pentyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea
-
-
N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea
-
-
N-tert-butyl-N'-[(2-(4'-methylphenylamino)-5-nitrobenzene)sulfonyl]urea
-
-
N-tert-butyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea
-
-
NO
-
irreversible in a concentration-dependent manner
prostaglandin H2
-
suicide inactivation
R68070
-
0.0000015 mM, 50% inhibition
ridogrel
-
0.000004 mM, 50% inhibition
samixogrel
-
0.000004 mM, 50% inhibition
Sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate
-
immobilized enzyme
Sodium 5-(3'pyridinylmethyl)benzofuran-2-carboxylate
-
-
Sodium p-benzyl-4-[1-oxo-2-(4-chlorobenzyl)-3-phenyl propyl]phenyl phosphonate
-
-
thromboxane A2
-
the production of thromboxane A2 by the enzyme is self-limiting, the enzyme is inactivated during the reaction
[3-[[Hydroxy[4-[3-methyl-2-(3-pyridinyl)indol-1-yl]butyl]phosphinyl]oxy]2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]acetic acid
-
-
[4-[3-Methyl-2-(3-pyridinyl)-1H-indol-1-yl]butyl]phosphonic acid
-
-
[4-[3-Methyl-2-(3-pyridinyl)-1H-indol-1-yl]butyl]phosphonic acid monoethyl ester
-
-
1-Benzylimidazole
-
immobilized enzyme
1-Benzylimidazole
-
special inhibitor of TXS
2-Isopropyl-3-nicotinylindole
-
-
2-Isopropyl-3-nicotinylindole
-
potent
4-{2-[(4-chlorophenyl)methyl]-3-phenylpropanoyl}phenyl hydrogen benzylphosphonate
-
i.e. N-0164
4-{2-[(4-chlorophenyl)methyl]-3-phenylpropanoyl}phenyl hydrogen benzylphosphonate
-
-
9alpha,11alpha-Methanoepoxy-15(S)-hydroxyprosta-5(cis)-13(trans)-dienoic acid
-
-
9alpha,11alpha-Methanoepoxy-15(S)-hydroxyprosta-5(cis)-13(trans)-dienoic acid
-
no inhibition
9alpha,11alpha-Methanoepoxy-15(S)-hydroxyprosta-5(cis)-13(trans)-dienoic acid
-
weak
dazoxiben
-
-
dazoxiben
-
competitive inhibitor
furegrelate
-
0.01 mM, 68% inhibition
furegrelate
-
cultures treated with show a reduced time-dependent increase in cell number compared with vehicle-treated cells. Addition to the growth medium results in reduction in cell invasion and reduction in cell migration.
furegrelate
-
specific inhibitor of thromboxane synthase, i.e. sodium 5-(3-pyridinylmethyl) benzofuran-2-carboxylate
furegrelate
-
specific inhibitor of TXSA
imidazole
-
and derivatives. The potency of 1-substituted imidazoles is increased as the side chain becomes more hydrophobic. Inhibition is competitive with respect to prostaglandin endoperoxide substrate
ozagrel
-
cultures treated with show a reduced time-dependent increase in cell number compared with vehicle-treated cells. Addition to the growth medium results in reduction in cell invasion and reduction in cell migration.
ozagrel
-
competitive inhibitor
additional information
-
overview
-
additional information
-
the enzyme is insensitive to sulfhydryl reagents and thiols
-
additional information
-
the enzyme is not affected by nonsteroidal antiinflammatory agents
-
additional information
-
development of a screening assay for the in vitro evaluation of thromboxane A2 synthase inhibitors. Inhibitors of thromboxane synthase are regarded as potentially useful agents in the treatment of cardiovascular diseases and in the prevention of tumor cell metastases
-
additional information
-
dual angiotensin converting enzyme/thromboxane synthase inhibitors
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis
A selective thromboxane synthetase inhibitor, OKY-046, fails to improve blood rheology in endotoxin-shocked rabbits.
Acidosis, Respiratory
Differential responses of porcine anterior spinal and middle cerebral arteries to carbon dioxide and pH.
Acute Coronary Syndrome
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
Acute Kidney Injury
Nephrotoxicity of cyclosporine: the role of platelet-activating factor and thromboxane.
Acute Kidney Injury
The protective effects of Iloprost and thromboxane synthetase inhibitor, UK 38485, against glycerol--induced acute renal failure in rats.
Acute Lung Injury
Differential effects of cyclo-oxygenase and thromboxane synthetase inhibition on ventilation-perfusion relationships in acid aspiration-induced acute lung injury.
Acute Lung Injury
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep.
Acute Lung Injury
Ketoconazole and pulmonary failure after esophagectomy: a prospective clinical trial.
Acute Lung Injury
Mediators of lung injury in mice following systemic activation of complement.
Acute Lung Injury
Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury.
Adenocarcinoma
Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).
Adenocarcinoma
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Adenocarcinoma
The effect of prostaglandin modulators on prostate tumor growth and metastasis.
Adenocarcinoma
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
Adenocarcinoma of Lung
Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase.
Albuminuria
Diverse associations between oxidative stress and thromboxane A2 in hypertensive glomerular injury.
Anaphylaxis
N-(heterocyclic alkyl)pyrido[2,1-b]quinazoline-8-carboxamides as orally active antiallergy agents.
Aneurysm
Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report.
Angina Pectoris
Selective thromboxane A2 synthetase inhibition in vasospastic angina pectoris.
Angina Pectoris
[Treatment of angina pectoris. New perspectives]
Angina, Stable
Failure of thromboxane synthetase inhibition to improve exercise tolerance in patients with stable angina pectoris.
Arrhythmias, Cardiac
Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion.
Arterial Occlusive Diseases
11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period.
Arterial Occlusive Diseases
The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
Arthritis, Experimental
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Asthma
A double-blind, placebo-controlled trial of the thromboxane synthetase blocker OKY-046 on bronchial hypersensitivity in bronchial asthma patients.
Asthma
Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients.
Asthma
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Asthma
Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma.
Asthma
Effect of OKY-046, a new thromboxane A2 synthetase inhibitor, on experimental asthma in guinea pigs.
Asthma
Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma.
Asthma
Genome-wide interaction study reveals age-dependent determinants of responsiveness to inhaled corticosteroids in individuals with asthma.
Asthma
Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma.
Asthma
The role of thromboxane in allergen-induced asthmatic responses.
Asthma
Therapeutic potential of thromboxane inhibitors in asthma.
Asthma
Thromboxane A2 and related prostaglandins in airways.
Asthma
Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.
Asthma
[Thromboxane A2 could be involved in bronchial hyperresponsiveness to methacholine in asthmatic subjects but not in bronchitic subjects]
Asthma
[Thromboxane A2 synthetase inhibitor in asthma therapy]
Astrocytoma
Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase.
Atherosclerosis
Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population.
Atherosclerosis
BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Atherosclerosis
Contribution of arachidonic acid metabolites to atherosclerosis.
Atherosclerosis
Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of Atherosclerosis.
Atherosclerosis
Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: Correlation with plaque composition.
Atherosclerosis
The combined use of prostaglandin I2 analogue (OP-2507) and thromboxane A2 synthetase inhibitor (OKY-046) strongly inhibits atherosclerosis of aortic allografts in rats.
Atherosclerosis
Thromboxane A synthase 1 gene expression and promotor haplotypes are associated with risk of large artery-atherosclerosis stroke in Iranian population.
Atherosclerosis
Thromboxane synthase expression and thromboxane A(2) production in the atherosclerotic lesion.
Atherosclerosis
[Treatment of angina pectoris. New perspectives]
Blood Platelet Disorders
[Genetic defects of prostaglandin and thromboxane synthesis]
Bone Resorption
The effect of imidazole-analogues on bone resorption in vitro: a suggested role for thromboxane A2.
Bradycardia
Direct and indirect effects of leukotriene D4 on the lungs of unanesthetized sheep.
Bradycardia
Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement.
Brain Ischemia
Effect of thromboxane synthetase inhibitor on cerebral circulation and metabolism during experimental cerebral ischemia in spontaneously hypertensive rats.
Brain Ischemia
Inhibition of thromboxane A2 production does not improve post-ischemic brain hypoperfusion in the dog.
Brain Ischemia
Role of platelets as a factor aggravating cerebral ischemia.
Brain Ischemia
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Brain Ischemia
Thromboxane synthetase inhibition in acute focal cerebral ischemia in cats.
Brain Ischemia
[Protective effect of thromboxane A2 synthetase inhibitor (trapidil) on acutely-induced cerebral ischemia]
Breast Neoplasms
Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.
Breast Neoplasms
Differential effects of tranylcypromine and imidazole on mammary carcinogenesis in rats fed low and high fat diets.
Breast Neoplasms
Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer.
Breast Neoplasms
Inhibiting breast cancer by targeting the thromboxane A2 pathway.
Bronchial Spasm
Effects of 1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3- (1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid with thromboxane A2 synthetase inhibitory and H1-blocking activities on anaphylactic bronchospasm.
Bronchial Spasm
Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs.
Bronchiectasis
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Bronchitis, Chronic
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Bronchitis, Chronic
Effect of thromboxane A2 synthetase inhibitor, OKY-046, on sputum in chronic bronchitis and diffuse panbronchiolitis.
Bronchitis, Chronic
[Thromboxane A2 could be involved in bronchial hyperresponsiveness to methacholine in asthmatic subjects but not in bronchitic subjects]
Calcinosis
The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition.
Carcinogenesis
Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells.
Carcinogenesis
Differential effects of tranylcypromine and imidazole on mammary carcinogenesis in rats fed low and high fat diets.
Carcinogenesis
Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells.
Carcinoma
Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.
Carcinoma
Correlation between metastatic patterns in renal cell carcinoma and tissue distribution of thromboxane synthetase.
Carcinoma
Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility.
Carcinoma
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Carcinoma
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Carcinoma
Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation.
Carcinoma
Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.
Carcinoma, Lewis Lung
Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.
Carcinoma, Non-Small-Cell Lung
18?-Glycyrrhetinic Acid Suppresses Cell Proliferation through Inhibiting Thromboxane Synthase in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Carcinoma, Non-Small-Cell Lung
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells.
Carcinoma, Renal Cell
Correlation between metastatic patterns in renal cell carcinoma and tissue distribution of thromboxane synthetase.
Carcinoma, Squamous Cell
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Carcinoma, Transitional Cell
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Carcinoma, Transitional Cell
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Cardiomyopathies
A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model.
Cardiovascular Diseases
Genomic structure and polymorphism of the human thromboxane synthase-encoding gene.
Cardiovascular Diseases
Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease.
Cerebral Infarction
Association of polymorphisms in thromboxane A2 receptor and thromboxane A synthase 1 with cerebral infarction in a Korean population.
Cerebral Infarction
Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits.
Cerebral Infarction
Thromboxane synthetase inhibition in acute focal cerebral ischemia in cats.
Cerebral Infarction
[Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery]
Cerebrovascular Disorders
Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Cerebrovascular Disorders
Testosterone treatment increases thromboxane function in rat cerebral arteries.
Cerebrovascular Disorders
The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Cerebrovascular Disorders
The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients.
Cerebrovascular Disorders
[Treatment of occlusive cerebrovascular disease with a selective thromboxane A2 synthetase inhibitor]
Cholestasis
The protective effect of thromboxane synthetase inhibitor UK 38485 against bile duct ligation induced liver injury.
Colitis
Prostaglandin regulation of colonic blood flow in rabbit colitis.
Colitis
Resolution of Cox mediated inflammation by Se supplementation in mouse experimental model of colitis.
Colitis
Thromboxane-prostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis.
Colitis, Ulcerative
Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Colitis, Ulcerative
Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
Colitis, Ulcerative
Thromboxane synthase immunohistochemistry in inflammatory bowel disease.
Colorectal Neoplasms
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2.
Congenital Abnormalities
Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation.
Congenital Abnormalities
Possible congenital defect in platelet thromboxane synthetase.
Coronary Artery Disease
Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise.
Coronary Artery Disease
Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease.
Coronary Artery Disease
Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
Coronary Artery Disease
EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin.
Coronary Artery Disease
[Pathogenetic and therapeutic significance of the angioprotective systems in patients with coronary arteriosclerosis]
Coronary Disease
Effects of dazoxiben on exercise performance in chronic stable angina.
Coronary Occlusion
Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Coronary Occlusion
Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion.
Coronary Occlusion
Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Coronary Occlusion
Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs.
Coronary Occlusion
Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
Coronary Occlusion
Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion.
Coronary Stenosis
Effect of the combination of anticoagulant and thromboxane synthetase inhibitor (Y-20811) or receptor blockade (S-1452) on preventing thrombotic cyclic coronary flow reduction in dogs with coronary stenosis.
Coronary Thrombosis
Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
Coronary Thrombosis
BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
Coronary Thrombosis
DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
Coronary Thrombosis
Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog.
Coronary Thrombosis
Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs.
Coronary Thrombosis
Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Coronary Thrombosis
Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Coronary Thrombosis
Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis.
Cough
Involvement of thromboxane A(2) in airway mucous cells in asthma-related cough.
Cough
Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors.
Cough
[Chronic persistent coughing successfully treated with ozagrel]
Crohn Disease
Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease.
Death, Sudden, Cardiac
Effects of combined thromboxane synthetase inhibition/thromboxane receptor antagonism in two models of sudden cardiac death in the canine: limited role for thromboxane.
Dementia
Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia.
Dementia
Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia.
Dementia, Vascular
Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia.
Dermatitis
Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice.
Diabetes Mellitus, Experimental
Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
Diabetes Mellitus, Experimental
Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia.
Diabetes Mellitus, Type 2
Prostaglandins and diabetic nephropathy.
Diabetes Mellitus, Type 2
Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy.
Diabetic Nephropathies
A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy.
Diabetic Nephropathies
Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
Diabetic Nephropathies
Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.
Diabetic Nephropathies
Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy.
Diabetic Retinopathy
Effects of high glucose concentration and a thromboxane synthase inhibitor on the production of thromboxane A2 and prostaglandin I2 and E2 by retinal endothelial cells.
Diabetic Retinopathy
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Diabetic Retinopathy
Specific thromboxane synthetase inhibition and retinopathy in insulin-dependent diabetics.
Disseminated Intravascular Coagulation
Role of activated platelets in endotoxin-induced DIC in rats.
Dyslipidemias
The effect of a thromboxane A2 synthase inhibitor on the dyslipoproteinemia of an inbred rat strain with spontaneous age-related nephrotic syndrome.
Dyslipidemias
Up-regulation of thromboxane A(2) impairs cerebrovascular eNOS function in aging atherosclerotic mice.
Embolic Stroke
[The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction]
Embolism, Air
Effect of thromboxane synthetase inhibitors (OKY-046, OKY-1580) on experimentally induced air embolism in anesthetized dogs.
Endometriosis
Anti-platelet therapy is efficacious in treating endometriosis induced in mouse.
Endotoxemia
Dazoxiben in human sepsis and adult respiratory distress syndrome.
Endotoxemia
Dose-dependent effects of a pyridoquinazoline thromboxane synthetase inhibitor on arachidonic acid metabolites and hemodynamics during E. coli endotoxemia in anesthetized sheep.
Endotoxemia
Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia.
Endotoxemia
Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor.
Endotoxemia
Protective effects of a thromboxane synthetase inhibitor and continuous arteriovenous hemofiltration in rat endotoxic shock.
Endotoxemia
The effect of thromboxane synthetase inhibition on cardiopulmonary function during endotoxemia in sheep.
Endotoxemia
Thromboxane synthase inhibition and cardiopulmonary function during endotoxemia in sheep.
Eosinophilia
Effects of a thromboxane synthase inhibitor (CS-518) on the eosinophil-dependent late asthmatic response and airway hyperresponsiveness in guinea pigs.
Epiretinal Membrane
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Erectile Dysfunction
Possible utility of a thromboxane synthetase inhibitor in preventing penile vascular changes and impotence during aging.
Erythema
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Essential Hypertension
Role of thromboxane A2 in the hypotensive effect of captopril in essential hypertension.
Essential Hypertension
Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
Familial Primary Pulmonary Hypertension
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Thromboxane synthetase inhibition in primary pulmonary hypertension.
Feline Infectious Peritonitis
Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats.
Fetal Growth Retardation
Effects of a thromboxane synthetase inhibitor (OKY-046) in an ischemia-reperfusion model of intrauterine growth retardation in Sprague-Dawley rats.
Fetal Growth Retardation
Lack of Thromboxane Synthase Prevents Hypertension and Fetal Growth Restriction after High Salt Treatment during Pregnancy.
Fibrosarcoma
Dissociation between thromboxane generation and metastatic potential in cells from a murine fibrosarcoma. Studies with a selective thromboxane synthase inhibitor.
Glioblastoma
Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.
Glioblastoma
Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.
Glioma
Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase.
Glioma
Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells.
Glioma
Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation.
Glioma
Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.
Glioma
Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.
Glioma
Thromboxane synthase inhibitors induce apoptosis in migration-arrested glioma cells.
Glioma
Thromboxane synthase regulates the migratory phenotype of human glioma cells.
Glioma
Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.
Glomerulonephritis
Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat.
Glomerulonephritis
Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury.
Glomerulonephritis
Effects of a selective thromboxane A2 synthetase inhibitor on immune complex glomerulonephritis.
Glomerulonephritis
Effects of a specific thromboxane synthetase inhibitor on development of experimental Dirofilaria immitis immune complex glomerulonephritis in the dog.
Glomerulonephritis
Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs.
Glomerulonephritis
Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis.
Glomerulonephritis
Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis.
Glomerulonephritis
Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
Glomerulonephritis
[Thromboxane A2 metabolism and clinical effects of selective thromboxane A2 synthetase inhibitor in patients with chronic glomerulonephritis]
Glomerulonephritis, IGA
Expression of thromboxane synthase in kidney tissues from patients with IgA nephropathy.
Glomerulonephritis, Membranoproliferative
Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
Glomerulonephritis, Membranous
Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats.
Gout
[Association of single nucleotide polymorphisms of cytochrome P450 gene with susceptibility to gout in ethnic Han males from coastal regions of Shandong province].
Heart Arrest
[Antagonism of collagen-induced ECG changes in rats by a thromboxane synthetase inhibitor, CV-4151]
Heart Diseases
Thromboxane synthase inhibition in patients with atherosclerotic heart disease.
Heart Failure
[Right heart function and endotoxemia in animals]
Hepatitis A
Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
Hepatitis C
Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
Hepatitis, Alcoholic
Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
Hernias, Diaphragmatic, Congenital
Extracorporeal membrane oxygenation and congenital diaphragmatic hernia: modification of the pulmonary vasoactive profile.
Hydronephrosis
Pharmacological manipulation of inflammation in rabbit hydronephrosis: effects of a combined cyclooxygenase/lipoxygenase inhibitor ethoxyquin, a thromboxane synthase inhibitor RS-5186 and a PAF antagonist L-659,989.
Hyperinsulinism
A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity.
Hypersensitivity
A double-blind, placebo-controlled trial of the thromboxane synthetase blocker OKY-046 on bronchial hypersensitivity in bronchial asthma patients.
Hypersensitivity
Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients.
Hypersensitivity
Effect of thromboxane A2 synthetase inhibitor on immediate-type hypersensitivity reactions.
Hypertension
Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension.
Hypertension
Attenuation of the development of hypertension in spontaneously hypertensive rats by the thromboxane synthetase inhibitor, 4'-(imidazol-1-yl) acetophenone.
Hypertension
Chronic thromboxane synthase inhibition prevents fructose-induced hypertension.
Hypertension
Contrasting effect of thromboxane synthase inhibitors and a thromboxane receptor antagonist on the development of angiotensin II-salt-induced hypertension in rats.
Hypertension
Cyclooxygenase pathway mediates lung injury induced by phorbol and platelets.
Hypertension
Cyclosporine-induced hypertension in sheep. The role of thromboxanes.
Hypertension
Delay of the initiation of hypertension in spontaneously hypertensive rats by CV-4151, a specific thromboxane A2 synthetase inhibitor.
Hypertension
Effects of continuous ingestion of hesperidin and glucosyl hesperidin on vascular gene expression in spontaneously hypertensive rats.
Hypertension
Endothelin-1 blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat.
Hypertension
Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets.
Hypertension
Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension.
Hypertension
Identification of Hub Genes Associated with Hypertension and Their Interaction with miRNA Based on Weighted Gene Coexpression Network Analysis (WGCNA) Analysis.
Hypertension
Lack of Thromboxane Synthase Prevents Hypertension and Fetal Growth Restriction after High Salt Treatment during Pregnancy.
Hypertension
Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel.
Hypertension
Novel oral prostacyclin analog with thromboxane synthase inhibitory activity for management of pulmonary arterial hypertension.
Hypertension
Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension.
Hypertension
Pharmacokinetics of furegrelate after oral administration to normal humans.
Hypertension
Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia.
Hypertension
Thromboxane A2 and development of genetic hypertension in the Lyon rat strain.
Hypertension
Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats.
Hypertension
Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats.
Hypertension
Thromboxane synthetase inhibitor UK38,485 lowers blood pressure in the adult spontaneously hypertensive rat.
Hypertension
[Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension]
Hypertension, Pregnancy-Induced
Beneficial effects of U-63,557A, a thromboxane synthetase inhibitor, in an ovine model of pregnancy-induced hypertension.
Hypertension, Pregnancy-Induced
Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension.
Hypertension, Pregnancy-Induced
Effects of thromboxane synthetase inhibition on maternal-fetal homeostasis in gravid ewes with ovine pregnancy-induced hypertension.
Hypertension, Pregnancy-Induced
Erythrocyte morphologic features and serum chemistry studies in ovine pregnancy-induced hypertension treated with thromboxane synthetase inhibitors.
Hypertension, Pregnancy-Induced
Preliminary observations on treatment of pregnancy-induced hypertension with a thromboxane synthetase inhibitor.
Hypertension, Pregnancy-Induced
Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension.
Hypertension, Pregnancy-Induced
Thromboxane synthetase inhibition in pregnancy-induced hypertension.
Hypertension, Pregnancy-Induced
Thromboxane synthetase inhibition produces maternal and fetal vasodilation during ovine pregnancy-induced hypertension: a Doppler flow velocimetric study.
Hypertension, Pulmonary
A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model.
Hypertension, Pulmonary
Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.
Hypertension, Pulmonary
Capsular type-specific polysaccharide partially inhibits group B Streptococcus-induced pulmonary hypertension.
Hypertension, Pulmonary
Dazoxiben in human sepsis and adult respiratory distress syndrome.
Hypertension, Pulmonary
Effect of blood and albumin on pulmonary hypertension and edema in perfused rabbit lungs.
Hypertension, Pulmonary
Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery.
Hypertension, Pulmonary
Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension.
Hypertension, Pulmonary
Extracorporeal membrane oxygenation and congenital diaphragmatic hernia: modification of the pulmonary vasoactive profile.
Hypertension, Pulmonary
Hyperbaric oxygen toxicity: role of thromboxane.
Hypertension, Pulmonary
Impact of prostaglandin and thromboxane synthesis blockade on disposition of group B streptococcus in lung and liver of intact piglet.
Hypertension, Pulmonary
In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase.
Hypertension, Pulmonary
Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade.
Hypertension, Pulmonary
Intrinsic microbicidal activity and pulmonary hypertension in isolated newborn piglet lungs.
Hypertension, Pulmonary
Lipoxygenase and cyclooxygenase blockade by BW755C does not prevent the secondary phase of septic pulmonary hypertension.
Hypertension, Pulmonary
Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581.
Hypertension, Pulmonary
Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury.
Hypertension, Pulmonary
Protein complex formation with heat shock protein 90 in chronic hypoxia-induced pulmonary hypertension in newborn piglets.
Hypertension, Pulmonary
Selective inhibition of thromboxane synthetase reduces group-B-beta-hemolytic-streptococci-induced pulmonary hypertension in piglets.
Hypertension, Pulmonary
Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets.
Hypertension, Pulmonary
Thromboxane-associated pulmonary hypertension during three types of gram-positive bacteremia in piglets.
Hypoparathyroidism
[Mechanisms of thrombocyte aggregation in experimental hypoparathyroidism]
Hypotension
Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue.
Hypotension
Possible involvement of thromboxane in bronchoconstrictive and hypertensive effects of LTC4 and LTD4 in guinea pigs.
Hypotension
Putative mechanism of hypotensive action of platelet-activating factor in dogs.
Hypotension
Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement.
Hypotension
Thromboxane synthase inhibition enhances action of converting enzyme inhibitors.
Infarction, Middle Cerebral Artery
Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
Infections
Indomethacin in vivo increases the sensitivity to Listeria infection in mice. A possible role for macrophage thromboxane A2 synthesis.
Infections
Trypanosoma cruzi infection and endothelin-1 cooperatively activate pathogenic inflammatory pathways in cardiomyocytes.
Inflammatory Bowel Diseases
Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors.
Inflammatory Bowel Diseases
Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease.
Inflammatory Bowel Diseases
Nv-52: a novel thromboxane synthase inhibitor for the treatment of inflammatory bowel disease.
Inflammatory Bowel Diseases
Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers.
Inflammatory Bowel Diseases
Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease.
Inflammatory Bowel Diseases
Thromboxane synthase immunohistochemistry in inflammatory bowel disease.
Insulin Resistance
Chronic thromboxane synthase inhibition prevents fructose-induced hypertension.
Intracranial Aneurysm
Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study.
Intracranial Embolism
Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits.
Intracranial Thrombosis
Clinical study on effect of thromboxane A2 synthetase inhibitor (OKY-046) to clarify the regulation of cerebral blood flow in cerebral thrombosis.
Intracranial Thrombosis
[Antithrombotic therapy in cerebral infarction]
Iron Overload
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
Ischemic Stroke
Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population.
Ischemic Stroke
Cinnamate Hybrids: A Unique Family of Compounds with Multiple Biological Activities.
Ischemic Stroke
Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction.
Ischemic Stroke
Variants in COX-2, PTGIS, and TBXAS1 Are Associated with Carotid Artery or Intracranial Arterial Stenosis and Neurologic Deterioration in Ischemic Stroke Patients.
Ischemic Stroke
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Ischemic Stroke
[Strategy for circulatory disturbance]
Ischemic Stroke
[The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction]
Kidney Diseases
Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease.
Kidney Diseases
The localization of thromboxane synthase in normal and pathological human kidney tissue using a monoclonal antibody Tü 300.
Kidney Diseases
Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney.
Leukemia
Differentiation-associated expression of prostaglandin H and thromboxane A synthases in monocytoid leukemia cell lines.
Leukemia
Manipulation of thromboxane synthesis by novel 26,27-dialkyl analogues of 1 alpha,25-dihydroxyvitamin D3 in human promyelocytic leukemia (HL-60) cells.
Leukemia, Erythroblastic, Acute
Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Induction of thromboxane synthase and prostaglandin endoperoxide synthase mRNAs in human erythroleukemia cells by phorbol ester.
Liver Diseases
Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis.
Liver Diseases, Alcoholic
Alterations in thromboxane synthase and thromboxane A2 receptors in experimental alcoholic liver disease.
Lung Injury
Effects of OKY-046, a selective thromboxane synthetase inhibitor, on endotoxin-induced lung injury in unanesthetized sheep.
Lung Injury
Effects of thromboxane synthase inhibition on air emboli lung injury in sheep.
Lung Injury
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep.
Lung Injury
Inhibition of cyclooxygenase metabolite production attenuates ischemia-reperfusion lung injury.
Lung Injury
Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs.
Lung Neoplasms
18?-Glycyrrhetinic Acid Suppresses Cell Proliferation through Inhibiting Thromboxane Synthase in Non-Small Cell Lung Cancer.
Lung Neoplasms
4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A(2) and its receptor.
Lung Neoplasms
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Lung Neoplasms
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.
Lung Neoplasms
Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27.
Lung Neoplasms
Thromboxane A2 receptor ? promotes tumor growth through an autoregulatory feedback pathway.
Lung Neoplasms
Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.
Lung Neoplasms
Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB.
Lung Neoplasms
Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells.
Lupus Erythematosus, Systemic
Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE.
Lupus Nephritis
Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
Lupus Nephritis
Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
Lupus Nephritis
Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis.
Lymphoma, Non-Hodgkin
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
Malaria, Cerebral
L-arginine supplementation and thromboxane synthase inhibition increases cerebral blood flow in experimental cerebral malaria.
Melanoma
Ketoconazole: a thromboxane synthetase and 5-lipoxygenase inhibitor with antimetastatic activity in B16-F10 melanoma.
Memory Disorders
Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia.
Mesenteric Ischemia
The effects of prostacyclin analogue ZK 36374 and thromboxane synthetase inhibitor UK 38485 on mesenteric ischemia in guinea pigs.
Mesothelioma
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
Mesothelioma, Malignant
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
Migraine Disorders
Thromboxane synthetase inhibition: potential therapy in migraine.
Mucocutaneous Lymph Node Syndrome
Implication of thromboxane in the pathogenesis of Kawasaki disease and a suggestion for using novel thromboxane synthetase inhibitors in its treatment.
Myocardial Infarction
Augmented thromboxane A2 generation and efficacy of its blockade in acute myocardial infarction.
Myocardial Infarction
BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
Myocardial Infarction
CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
Myocardial Infarction
Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Myocardial Infarction
Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046).
Myocardial Infarction
Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Myocardial Infarction
Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model.
Myocardial Infarction
Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
Myocardial Infarction
Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
Myocardial Infarction
Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
Myocardial Infarction
Role of a genetic variation in the promoter of human thromboxane synthase gene in myocardial infarction.
Myocardial Infarction
The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models.
Myocardial Infarction
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Myocardial Infarction
[Association of Rs10487667 genetic polymorphism of thromboxane synthase with myocardial infarction in Uigur population of Xinjiang].
Myocardial Infarction
[Association of the Pro1770Leu polymorphism in CYP5A1 gene with myocardial infarction in Uigur population of Xinjiang.]
Myocardial Ischemia
A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model.
Myocardial Ischemia
Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia.
Myocardial Ischemia
Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease.
Myocardial Ischemia
Improved lactate extraction in dogs with coronary artery ligation following administration of a thromboxane synthetase inhibitor.
Myocardial Ischemia
Inhibition of thromboxane synthetase by the imidazole derivative 3-(1H-imidazol-1-yl-methyl)-2-methyl-1H-indole-1-propanoic acid as a novel therapeutic approach to experimental myocardial ischemia.
Myocardial Ischemia
Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium.
Myocardial Ischemia
Salutary actions of thromboxane synthetase inhibition during global myocardial ischemia.
Myocardial Ischemia
Selective thromboxane synthetase inhibitor and ischemic heart disease.
Myocardial Ischemia
The effect of beta-adrenoceptor blockade and of thromboxane synthetase inhibition, alone and in combination, on arrhythmias resulting from myocardial ischemia.
Myocardial Stunning
Prostaglandin redirection by thromboxane synthetase inhibition. Attenuation of myocardial stunning in canine heart.
Neonatal Sepsis
Effects of the thromboxane synthetase inhibitor, dazmegrel (UK 38,485), on pulmonary gas exchange and hemodynamics in neonatal sepsis.
Neoplasm Metastasis
Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein -1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells.
Neoplasm Metastasis
Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575).
Neoplasm Metastasis
Eicosanoids and metastasis: experimental aspects in Lewis lung carcinoma.
Neoplasm Metastasis
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Neoplasm Metastasis
Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor.
Neoplasm Metastasis
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Neoplasm Metastasis
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
Neoplasm Metastasis
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
Neoplasm Metastasis
The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer.
Neoplasm Metastasis
The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.
Neoplasm Metastasis
Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.
Neoplasm Metastasis
Thromboxane synthase and organ preference for metastases.
Neoplasms
Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells.
Neoplasms
Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein -1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells.
Neoplasms
Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.
Neoplasms
Apigenin inhibits tumor necrosis factor alpha plus high glucose induced-LOX-1 expression in human endothelial cells.
Neoplasms
Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases.
Neoplasms
Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575).
Neoplasms
Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.
Neoplasms
Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility.
Neoplasms
Effects of systemic complement activation and neutrophil-mediated pulmonary injury on the retention and metastasis of circulating cancer cells in mouse lungs.
Neoplasms
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep.
Neoplasms
Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis.
Neoplasms
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.
Neoplasms
Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer.
Neoplasms
G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis.
Neoplasms
Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.
Neoplasms
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Neoplasms
Phenotypic properties of cultured tumor cells: integrin alpha IIb beta 3 expression, tumor-cell-induced platelet aggregation, and tumor-cell adhesion to endothelium as important parameters of experimental metastasis.
Neoplasms
Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor.
Neoplasms
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Neoplasms
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
Neoplasms
Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia.
Neoplasms
Role of postaglandins in metastatic dissemination of cancer. Minireview on cancer research.
Neoplasms
Role of prostaglandins in metastatic dissemination of cancer. Minireview on cancer research.
Neoplasms
The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy.
Neoplasms
The formation of thromboxane B2, leukotriene B4 and 12-hydroxyeicosatetraenoic acid by alveolar macrophages after activation during tumor growth in the rat.
Neoplasms
The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
Neoplasms
The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer.
Neoplasms
The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.
Neoplasms
Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells.
Neoplasms
Thromboxane A2 receptor ? promotes tumor growth through an autoregulatory feedback pathway.
Neoplasms
Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho.
Neoplasms
Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.
Neoplasms
Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB.
Neoplasms
Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.
Neoplasms
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2.
Nephritis
Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats.
Nephritis
Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats.
Nephritis
Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury.
Nephritis
Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase.
Nephritis
Rabbit nephrotoxic nephritis: effect of a thromboxane synthetase inhibitor on evolution and prostaglandin excretion.
Nephritis
The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse.
Nephritis
The role of arachidonic acid metabolites in renal homeostasis. Non-steroidal anti-inflammatory drugs renal function and biochemical, histological and clinical effects and drug interactions.
Nephritis
Trial of platelet-derived growth factor antagonist, trapidil, in accelerated nephrotoxic nephritis in the rabbit.
Nephrotic Syndrome
Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome.
Nephrotic Syndrome
The effect of a thromboxane A2 synthase inhibitor on the dyslipoproteinemia of an inbred rat strain with spontaneous age-related nephrotic syndrome.
Nephrotic Syndrome
Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
Nephrotic Syndrome
[The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation]
Neuroinflammatory Diseases
Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia.
Neuroinflammatory Diseases
Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia.
Obesity
A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity.
Obesity
Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression.
Pancreatic Neoplasms
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints.
Pancytopenia
Chronic steroid-response pancytopenia and increased bone density due to thromboxane synthase deficiency.
Peripheral Arterial Disease
Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
Peripheral Arterial Disease
Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.
Peripheral Arterial Disease
Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
Peripheral Vascular Diseases
Initial impressions of dazoxiben in the treatment of the ischaemic limb.
Peritonitis
Acute renal failure and sepsis: therapeutic approaches.
Peritonitis
Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats.
Peritonitis
Gentamicin and indomethacin in the treatment of septic shock: effects on prostacyclin and thromboxane A2 production.
Pituitary Neoplasms
Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.
Pleurisy
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Pre-Eclampsia
Antithromboxane drug in the treatment of preeclampsia.
Pre-Eclampsia
Effects of a thromboxane synthetase inhibitor on platelet function; possible risks of use in pregnancy.
Pre-Eclampsia
Effects of thromboxane synthetase inhibition on maternal-fetal homeostasis in gravid ewes with ovine pregnancy-induced hypertension.
Pre-Eclampsia
Effects of thromboxane synthetase inhibitor (OKY-046) on placental blood flow, placental weight and fetal weight in normotensive and spontaneously hypertensive rats.
Pre-Eclampsia
Eicosanoid biosynthetic enzymes in placental and decidual tissues from preeclamptic pregnancies: increased expression of thromboxane-A2 synthase gene.
Pre-Eclampsia
Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia.
Pre-Eclampsia
The possibility of clinical application of the thromboxane A2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: a preliminary report.
Pre-Eclampsia
Thromboxane synthetase inhibition as a new therapy for preeclampsia: animal and human studies minireview.
Proteinuria
Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives.
Proteinuria
Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats.
Proteinuria
Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE.
Proteinuria
Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
Proteinuria
[Effects of a selective thromboxane A2 synthetase inhibitor, OKY-046, on proteinuria of aminonucleoside nephrotic rats]
Proteinuria
[The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation]
Pulmonary Arterial Hypertension
Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets.
Pulmonary Arterial Hypertension
Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel.
Pulmonary Arterial Hypertension
Novel oral prostacyclin analog with thromboxane synthase inhibitory activity for management of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension.
Pulmonary Edema
Alpha-thrombin-induced pulmonary vasoconstriction.
Pulmonary Embolism
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
Pulmonary Embolism
Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
Pulmonary Embolism
Effect of OKY 046, a thromboxane synthase inhibitor, on lung vascular permeability after pulmonary embolism in sheep.
Pulmonary Embolism
Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat.
Pulmonary Eosinophilia
Suppressive effects of F-1322 on the antigen-induced late asthmatic response and pulmonary eosinophilia in guinea pigs.
Pulmonary Fibrosis
Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice.
Renal Insufficiency
Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
Renal Insufficiency
Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats.
Reperfusion Injury
Effects of thromboxane A2 synthetase inhibitor (CV-4151) on reperfused skeletal muscle in rats.
Reperfusion Injury
Protective effect of FK506 and thromboxane synthase inhibitor on ischemia-reperfusion injury in non-heart-beating donor in rat orthotopic liver transplantation.
Reperfusion Injury
Reduction of reperfusion injury in rat skeletal muscle following administration of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Reperfusion Injury
The effects of thromboxane synthase inhibition on reperfusion injury and endothelin-1,2 levels in allograft kidney transplantation in rats.
Respiratory Distress Syndrome
A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome.
Respiratory Distress Syndrome
Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome.
Respiratory Distress Syndrome
Role of arachidonic acid metabolites in oleic acid induced pulmonary injury in a canine model. Effect of ketoconazole (thromboxane synthetase inhibitor).
Respiratory Insufficiency
[Protective effect of a thromboxane synthetase inhibitor, OKY-046, in patients with acute respiratory failure]
Respiratory Insufficiency
[The effect of cyclooxygenase and thromboxane synthetase inhibition on oxygen metabolism in canine acute respiratory failure]
Scleroderma, Systemic
Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis.
Seizures
The effect of inhibiting brain thromboxane biosynthesis on pentylenetetrazole-induced seizure threshold.
Sepsis
Effects of a specific thromboxane synthetase inhibitor in equine endotoxaemia.
Sepsis
Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension.
Sepsis
Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel.
Sepsis
The protective effect of thromboxane synthetase inhibition on renal function in systemic sepsis.
Sepsis
Thromboxane synthetase inhibition and thromboxane receptor blockade preserve pulmonary and circulatory function in a porcine burn sepsis model.
Sepsis
Thromboxane synthetase inhibitors in septic shock.
Shock, Septic
A selective thromboxane synthetase inhibitor, OKY-046, fails to improve blood rheology in endotoxin-shocked rabbits.
Shock, Septic
Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia.
Shock, Septic
Induction of cytosolic phospholipase A2 and prostaglandin H2 synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes.
Shock, Septic
Protection of myocardial function during endotoxin shock by ibuprofen.
Shock, Septic
Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits.
Shock, Septic
Protective effects of thromboxane A2 synthetase inhibitors on endotoxin shock.
Shock, Septic
Thromboxane synthetase inhibitors in septic shock.
Small Cell Lung Carcinoma
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Spasm
Intracoronary administration of a thromboxane A2 synthase inhibitor relieves acetylcholine-induced coronary spasm.
Spasm
Roles of thromboxanes in gastrointestinal physiopathology.
Stroke
Effects of Furegrelate (Upjohn 63557A) on patency and platelet deposition after canine carotid endarterectomy.
Stroke
Interactions among Variants in Eicosanoid Genes Increase Risk of Atherothrombotic Stroke in Chinese Populations.
Stroke
Interference of levamisole with cerebral edema.
Stroke
N2 ameliorates neural injury during experimental ischemic stroke via the regulation of thromboxane A2 production.
Stroke
Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase.
Stroke
The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients.
Stroke
Thromboxane A synthase 1 gene expression and promotor haplotypes are associated with risk of large artery-atherosclerosis stroke in Iranian population.
Stroke
Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats.
Stroke
Thromboxane A2 synthetase inhibitor plus low dose aspirin : can it be a salvage treatment in acute stroke beyond thrombolytic time window.
Stroke
[Strategy for circulatory disturbance]
Stroke, Lacunar
[Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction]
Subarachnoid Hemorrhage
Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Effect of diltiazem and thromboxane A2 synthetase inhibitor (OKY-046) on vessels following experimental subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Effect of selective inhibitor of thromboxane A2 synthetase on cerebral vasospasm after early surgery.
Subarachnoid Hemorrhage
Effects of subarachnoid hemorrhage and a thromboxane A2 synthetase inhibitor on intracranial prostaglandins.
Subarachnoid Hemorrhage
Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581.
Subarachnoid Hemorrhage
[Experimental study on the prevention of vasospasm following subarachnoid hemorrhage by a thromboxane A2 synthetase inhibitor, OKY-046]
Subarachnoid Hemorrhage
[Prevention of vasospasm following subarachnoid hemorrhage using a thromboxane A2 synthetase inhibitor (OKY-046)--clinical study among multiple institutions]
Tachycardia, Ventricular
Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Tachycardia, Ventricular
Thromboxane A2 does not contribute to arrhythmogenesis during evolving canine myocardial infarction.
Thrombocytopenia
CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Thrombocytopenia
Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig.
Thrombocytopenia
Platelet-lung in vivo interactions: an artifact of a multi-purpose model?
Thrombocytopenia
Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.
Thromboembolism
Cerebral platelet thromboembolism and thromboxane synthetase inhibition.
Thromboembolism
Mechanism of action of dipyridamole.
Thrombosis
8th Seah Cheng Siang Memorial Lecture: new antithrombotic agents.
Thrombosis
A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Thrombosis
Action of selective inhibitor of thromboxane synthetase on experimental thrombosis induced by arachidonic acid in rabbits.
Thrombosis
Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with thromboxane synthetase inhibitor dazoxiben hydrochloride, (UK-37, 248-01).
Thrombosis
Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
Thrombosis
Carrageenin-induced thrombosis in the rat and mouse as a test model of substances influencing thrombosis.
Thrombosis
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Thrombosis
Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.
Thrombosis
Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
Thrombosis
Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
Thrombosis
Effect of dazoxiben on arterial graft thrombosis in the baboon.
Thrombosis
Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
Thrombosis
Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
Thrombosis
Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Thrombosis
Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury.
Thrombosis
Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Thrombosis
Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Thrombosis
Exchange of cyclooxygenase dependent metabolites between vessel wall and platelets in arterial thrombosis.
Thrombosis
Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: evidence for alternate pathways for coronary thrombosis.
Thrombosis
Fibrin, red cell and platelet interactions in an experimental model of thrombosis.
Thrombosis
Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
Thrombosis
Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents.
Thrombosis
Microsurgical carotid endarterectomy in rats.
Thrombosis
Oxygen-free radicals and nitric oxide are involved in the thrombus growth produced by iontophoresis of ADP.
Thrombosis
Percutaneous transluminal angioplasty increases thromboxane A2 production in claudicants.
Thrombosis
Pharmacokinetics of furegrelate after oral administration to normal humans.
Thrombosis
Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Thrombosis
Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Thrombosis
Photochemically induced thrombosis of the rat coronary artery and functional evaluation of thrombus formation by occurrence of ventricular arrhythmias. Effects of acetylsalicylic acid and a thromboxane A2 synthetase inhibitor of thrombus formation.
Thrombosis
Prostaglandin endoperoxides and thromboxane A2 in thrombus formation in the hamster cheek pouch in vivo.
Thrombosis
Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Thrombosis
Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Thrombosis
Testosterone treatment increases thromboxane function in rat cerebral arteries.
Thrombosis
The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists.
Thrombosis
The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding.
Thrombosis
The effect of platelet inhibitory therapy on graft thromboresistance.
Thrombotic Microangiopathies
The localization of thromboxane synthase in normal and pathological human kidney tissue using a monoclonal antibody Tü 300.
thromboxane-a synthase deficiency
Chronic steroid-response pancytopenia and increased bone density due to thromboxane synthase deficiency.
thromboxane-a synthase deficiency
Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism.
thromboxane-a synthase deficiency
Hereditary bleeding disorder due to a primary defect in platelet release reaction.
thromboxane-a synthase deficiency
Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder.
thromboxane-a synthase deficiency
Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.
thromboxane-a synthase deficiency
Thromboxane synthase deficiency improves insulin action and attenuates adipose tissue fibrosis.
thromboxane-a synthase deficiency
[Deficiencies of the prostaglandin system: III. A partial thromboxane synthetase defect]
thromboxane-a synthase deficiency
[Platelet thromboxane synthase deficiency]
Thyroid Cancer, Papillary
Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth.
Toxemia
Fetal and maternal response to intravenous infusion of a thromboxane synthetase inhibitor.
Ureteral Obstruction
Effect of thromboxane inhibition on renal blood flow in dogs with complete unilateral ureteral obstruction.
Urinary Bladder Neoplasms
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Urinary Bladder Neoplasms
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Urinary Bladder Neoplasms
Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoring.
Vascular Diseases
Thromboxane A(2) increases endothelial permeability through upregulation of interleukin-8.
Vascular Diseases
Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells.
Vascular System Injuries
Genetic Depletion of Thromboxane A2/Thromboxane-Prostanoid Receptor Signalling Prevents Microvascular Dysfunction in Ischaemia/Reperfusion Injury.
Vasospasm, Intracranial
Beneficial effect of OKY-046, a selective thromboxane A2 synthetase inhibitor, on experimental cerebral vasospasm.
Vasospasm, Intracranial
Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study.
Vasospasm, Intracranial
Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage.
Vasospasm, Intracranial
Effect of selective inhibitor of thromboxane A2 synthetase on cerebral vasospasm after early surgery.
Vasospasm, Intracranial
Effect of selective inhibitor of thromboxane A2 synthetase on experimental cerebral vasospasm.
Vasospasm, Intracranial
Effects of thromboxane synthetase inhibitor (RS-5186) on experimentally-induced cerebral vasospasm.
Vasospasm, Intracranial
Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage.
Vasospasm, Intracranial
Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581.
Vasospasm, Intracranial
Prevention of cerebral vasospasm with OKY-046 an imidazole derivative and a thromboxane synthetase inhibitor. A preliminary co-operative clinical study.
Vasospasm, Intracranial
Prostacyclin and thromboxane in cerebral vasospasm II: Effects of thromboxane synthetase inhibitor (OKY-1581) on experimentally-induced cerebral vasospasm.
Vasospasm, Intracranial
Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report.
Vasospasm, Intracranial
Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm.
Ventricular Fibrillation
Arachidonic acid cascade and the generation of ischemia- and reperfusion-induced ventricular arrhythmias.
Ventricular Fibrillation
Comments on "The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs".
Ventricular Fibrillation
Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion.
Ventricular Fibrillation
Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Ventricular Fibrillation
Interaction of platelets with the vessel wall in the pathophysiology of sudden cardiac death.
Ventricular Fibrillation
The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Hecker, M.; Haurand, M.; Ullrich, V.; Diczfalusy, U.; Hammarstrm, S.
Products, kinetics, and substrate specificity of homogeneous thromboxane synthase from human platelets: development of a novel enzyme assay
Arch. Biochem. Biophys.
254
124-135
1987
Homo sapiens
brenda
Hall, E.R.; Tuan, W.; Venton, D.L.
Production of platelet thromboxane A2 inactivates purified human platelet thromboxane synthase
Biochem. J.
233
637-641
1986
Homo sapiens
brenda
Haurand, M.; Ullrich, V.
Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme
J. Biol. Chem.
260
15059-15067
1985
Homo sapiens
brenda
Hecker, M.; Baader, W.J.; Weber, P.; Ullrich, V.
Thromboxane synthase catalyses hydroxylations of prostaglandin H2 analogs in the presence of iodosylbenzene
Eur. J. Biochem.
169
563-569
1987
Homo sapiens
brenda
Gorman, R.R.
Biology and biochemistry of thromboxane synthetase inhibitors
Adv. Prostaglandin Thromboxane Leukot. Res.
11
235-240
1983
Homo sapiens
brenda
Ullrich, V.; Haurand, M.
Thromboxane synthase as a cytochrome P450 enzyme
Adv. Prostaglandin Thromboxane Leukot. Res.
11
105-110
1983
Homo sapiens
brenda
Hammarstroem, S.
Enzymatic synthesis of 15-hydroperoxythromboxane A2 and 12-hydroperoxy-5,8,10-heptadecatrienoic acid
J. Biol. Chem.
255
518-521
1980
Homo sapiens
brenda
Hammarstroem, S.; Diczfalusy, U.
Inhibition and properties of thromboxane synthetase
Adv. Inflamm. Res.
1
431-438
1979
Homo sapiens
-
brenda
Tai, H.H.; Yuan, B.
On the inhibitory potency of imidazole and its derivatives on thromboxane synthetase
Biochem. Biophys. Res. Commun.
80
236-242
1978
Homo sapiens
brenda
Diczfalusy, U.; Falardeau, P.; Hammarstrm, S.
Conversion of prostaglandin endoperoxides to C17-hydroxy acids catalyzed by human platelet thromboxane synthase
FEBS Lett.
84
271-274
1977
Homo sapiens
brenda
Diczfalusy, U.; Hammarstrm, S.
Inhibitors of thromboxane synthase in human platelets
FEBS Lett.
82
107-110
1977
Homo sapiens
brenda
Hammarstroem, S.; Falardeau, P.
Resolution of prostaglandin synthase and thromboxane synthase of human platelets
Proc. Natl. Acad. Sci. USA
74
3691-3695
1977
Homo sapiens
brenda
Sun, F.F.
Biosynthesis of thromboxanes in human platelets. I. Characterization and assay of thromboxane synthetase
Biochem. Biophys. Res. Commun.
74
1432-1440
1977
Homo sapiens
brenda
Ullrich, V.; Nusing, R.
Thromboxane synthase. From isolation to function
Stroke
21
IV134-IV138
1994
Homo sapiens
brenda
Umemura, K.; Nakashima, M.; Saruta, T.
Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors
Life Sci.
60
1583-1588
1997
Homo sapiens
brenda
Ledergerber, D.; Hartmann, R.W.
Development of a screening assay for the in vitro evaluation of the thromboxane A2 synthase inhibitors
J. Enzyme Inhib.
9
253-261
1995
Homo sapiens
brenda
Yoshida, T.; Kameda, H.; Masashi, A.; Homma, M.; Ikeda, Y.
Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in Lupus nephritis
Adv. Exp. Med. Biol.
433
113-117
1997
Homo sapiens
brenda
Miyata, A.; Yokoyama, C.; Ihara, H.; Bandoh, S.; Takeda, O.; Takahashi, E.I.; Tanabe, T.
Characterization of the human gene (TBXAS1) encoding thromboxane synthase
Eur. J. Biochem.
224
273-279
1994
Homo sapiens
brenda
Lee, S.J.; Konishi, Y.; Yu, D.T.; Miskowski, T.A.; Riviello, C.M.; Macina, O.T.; Frierson, M.R.; Kondo, K.; Sugitani, M.; Suvar, J.C.; Blazejewski, K.M.
Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities
J. Med. Chem.
38
3547-3557
1995
Homo sapiens, Rattus norvegicus
brenda
Dickinson, R.P.; Dack, K.N.; Long, C.J.; Steele, J.
Thromboxane modulating agents. 3. 1H-Imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists
J. Med. Chem.
40
3442-3452
1997
Homo sapiens
brenda
Ksander, G.M.; Erion, M.; Yuan, A.M.; Diefenbacher, C.G.; El-Chebabi, L.; Cote, D.; Levens, N.
Dual angiotensin converting enzyme/thromboxane synthase inhibitors
J. Med. Chem.
37
1823-1832
1994
Homo sapiens
brenda
Ruan, K.H.; Milfeld, K.; Kulmacz, R.J.; Wu, K.K.
Comparison of the construction of a 3-D model for human thromboxane synthase using P450cam and BM-3 as templates: implications for the substrate binding pocket
Protein Eng.
7
1345-1351
1994
Homo sapiens
brenda
Nusing, R.; Schneider-Voss, S.; Ullrich, V.
Immunoaffinity purification of human thromboxane synthase
Arch. Biochem. Biophys.
280
325-330
1990
Homo sapiens
brenda
Orlandi, M.; Bartolini, G.; Belletti, B.; Spisni, E.; Tomasi, V.
Thromboxane A2 synthase activity in platelet free human monocytes
Biochim. Biophys. Acta
1215
285-290
1994
Homo sapiens
brenda
Uematsu, T.; Kosuge, K.; Umemura, M.; Nakano, M.; Terakawa, M.; Nakashima, M.
Pharmacokinetic and pharmacodynamic properties of FK070(KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers
J. Pharm. Pharmacol.
48
380-385
1996
Homo sapiens
brenda
Jones, D.A.; Fitzpatrick, F.A.
"Suicide" inactivation of thromboxane A2 synthase. Characteristics of mechanism-based inactivation with isolated enzyme and intact platelets
J. Biol. Chem.
265
20166-20171
1990
Bos taurus, Homo sapiens
brenda
Haurand, M.; Ullrich, V.
Thromboxane synthase and prostacyclin synthase as P-450 enzymes with regard to the mechanisms of PGI2 and TXA2 biosynthesis
Front. Biotransform.
6
183-199
1992
Homo sapiens, Sus scrofa
-
brenda
Wade, M.L.; Fitzpatrick, F.A.
Nitric oxide modulates the activity of the hemoproteins prostaglandin I2 synthase and thromboxane A2 synthase
Arch. Biochem. Biophys.
347
174-180
1997
Homo sapiens
brenda
Michaux, C.; Norberg, B.; Dogne, J.M.; Durant, F.; Masereel, B.; Delarge, J.; Wouters, J.
Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition
Acta Crystallogr. Sect. C
56
1265-1266
2000
Homo sapiens
-
brenda
Michaux, C.; Dogne, J.M.; Norberg, B.; Durant, F.; Masereel, B.
N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition
Acta Crystallogr. Sect. C
58
o621-623
2002
Homo sapiens
brenda
Hsu, P.Y.; Tsai, A.L.; Wang, L.H.
Identification of thromboxane synthase amino acid residues involved in heme-propionate binding
Arch. Biochem. Biophys.
383
119-127
2000
Homo sapiens
brenda
Chen, Z.; Wang, L.H.; Schelvis, J.P.
Resonance Raman investigation of the interaction of thromboxane synthase with substrate analogues
Biochemistry
42
2542-2551
2003
Homo sapiens
brenda
Michaux, C.; Dogne, J.M.; Rolin, S.; Masereel, B.; Wouters, J.; Durant, F.
A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors
Eur. J. Med. Chem.
38
703-710
2003
Homo sapiens
brenda
Borsch-Haubold, A.G.; Pasquet, S.; Watson, S.P.
Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase
J. Biol. Chem.
273
28766-28772
1998
Homo sapiens
brenda
Hsu, P.Y.; Tsai, A.L.; Kulmacz, R.J.; Wang, L.H.
Expression, purification, and spectroscopic characterization of human thromboxane synthase
J. Biol. Chem.
274
762-769
1999
Homo sapiens
brenda
Wang, L.H.; Tsai, A.L.; Hsu, P.Y.
Substrate binding is the rate-limiting step in thromboxane synthase catalysis
J. Biol. Chem.
276
14737-14743
2001
Homo sapiens
brenda
Takeuchi, K.; Kohn, T.J.; True, T.A.; Mais, D.E.; Wikel, J.H.; Utterback, B.G.; Wyss, V.L.; Jakubowski, J.A.
Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds
J. Med. Chem.
41
5362-5374
1998
Homo sapiens
brenda
Soyka, R.; Guth, B.D.; Weisenberger, H.M.; Luger, P.; Muller, T.H.
Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors
J. Med. Chem.
42
1235-1249
1999
Homo sapiens
brenda
Jacobs, C.; Frotscher, M.; Dannhardt, G.; Hartmann, R.W.
1-Imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase
J. Med. Chem.
43
1841-1851
2000
Homo sapiens
brenda
Dogne, J.M.; Wouters, J.; Rolin, S.; Michaux, C.; Pochet, L.; Durant, F.; Delarge, J.; Masereel, B.
Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor
J. Pharm. Pharmacol.
53
669-680
2001
Homo sapiens
brenda
Villalobos, M.A.; De La Cruz, J.P.; Escalante, R.; Arrebola, M.M.; Guerrero, A.; Sanchez de la Cuesta, F.
Effects of camonagrel, a selective inhibitor of platelet thromboxane synthase, on the platelet-subendothelium interaction
Pharmacology
69
44-50
2003
Homo sapiens
brenda
Nie, D.; Che, M.; Zacharek, A.; Qiao, Y.; Li, L.; Li, X.; Lamberti, M.; Tang, K.; Cai, Y.; Guo, Y.; Grignon, D.; Honn, K.V.
Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility
Am. J. Pathol.
164
429-439
2004
Homo sapiens
brenda
Moussa, O.; Yordy, J.S.; Abol-Enein, H.; Sinha, D.; Bissada, N.K.; Halushka, P.V.; Ghoneim, M.A.; Watson, D.K.
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer
Cancer Res.
65
11581-11587
2005
Homo sapiens
brenda
Stachowska, E.; Dolegowska, B.; Olszewska, M.; Gutowska, I.; Chlubek, D.
Isomers of trans fatty acids modify the activity of platelet 12-P lipoxygenase and cyclooxygenase/thromboxane synthase
Nutrition
20
570-571
2004
Homo sapiens
brenda
Yeh, H.C.; Tsai, A.L.; Wang, L.H.
Reaction mechanisms of 15-hydroperoxyeicosatetraenoic acid catalyzed by human prostacyclin and thromboxane synthases
Arch. Biochem. Biophys.
461
159-168
2007
Homo sapiens
brenda
Sakai, H.; Suzuki, T.; Takahashi, Y.; Ukai, M.; Tauchi, K.; Fujii, T.; Horikawa, N.; Minamimura, T.; Tabuchi, Y.; Morii, M.; Tsukada, K.; Takeguchi, N.
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2
FEBS Lett.
580
3368-3374
2006
Homo sapiens
brenda
Cailleteau, C.; Liagre, B.; Battu, S.; Jayat-Vignoles, C.; Beneytout, J.L.
Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells
Anal. Biochem.
380
26-34
2008
Homo sapiens
brenda
Cheng, F.C.; Feng, J.J.; Chen, K.H.; Imanishi, H.; Fujishima, M.; Takekoshi, H.; Naoki, Y.; Shimoda, M.
Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases
Int. J. Food Sci. Nutr.
60 Suppl 1
89-98
2008
Homo sapiens
brenda
Genevieve, D.; Proulle, V.; Isidor, B.; Bellais, S.; Serre, V.; Djouadi, F.; Picard, C.; Vignon-Savoye, C.; Bader-Meunier, B.; Blanche, S.; de Vernejoul, M.C.; Legeai-Mallet, L.; Fischer, A.M.; Le Merrer, M.; Dreyfus, M.; Gaussem, P.; Munnich, A.; Cormier-Daire, V.
Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome)
Nat. Genet.
40
284-286
2008
Homo sapiens
brenda
Vila, L.; Martinez-Perez, A.; Camacho, M.; Buil, A.; Alcolea, S.; Pujol-Moix, N.; Soler, M.; Anton, R.; Souto, J.C.; Fontcuberta, J.; Soria, J.M.
Heritability of thromboxane A2 and prostaglandin E2 biosynthetic machinery in a Spanish population
Arterioscler. Thromb. Vasc. Biol.
30
128-134
2010
Homo sapiens
brenda
Cathcart, M.C.; Reynolds, J.V.; OByrne, K.J.; Pidgeon, G.P.
The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer
Biochim. Biophys. Acta
1805
153-166
2010
Homo sapiens
brenda
Park, S.A.; Park, B.L.; Park, J.H.; Lee, T.K.; Sung, K.B.; Lee, Y.K.; Chang, H.S.; Park, C.S.; Shin, H.D.
Association of polymorphisms in thromboxane A2 receptor and thromboxane A synthase 1 with cerebral infarction in a Korean population
BMB Rep.
42
200-205
2009
Homo sapiens
brenda
Leung, K.C.; Hsin, M.K.; Chan, J.S.; Yip, J.H.; Li, M.; Leung, B.C.; Mok, T.S.; Warner, T.D.; Underwood, M.J.; Chen, G.G.
Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27
Exp. Cell Res.
315
2974-2981
2009
Homo sapiens
brenda
Gabrielsen, A.; Qiu, H.; Baeck, M.; Hamberg, M.; Hemdahl, A.L.; Agardh, H.; Folkersen, L.; Swedenborg, J.; Hedin, U.; Paulsson-Berne, G.; Haeggstroem, J.Z.; Hansson, G.K.
Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion
J. Mol. Med.
88
795-806
2010
Homo sapiens, Mus musculus
brenda
Schauff, A.; Kim, E.; Leppert, J.; Nadrowitz, R.; Wuestenberg, R.; Brockmann, M.; Giese, A.
Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation
J. Neurooncol.
91
241-249
2009
Homo sapiens
brenda
Schmidt, N.O.; Ziu, M.; Cargioli, T.; Westphal, M.; Giese, A.; Black, P.M.; Carroll, R.S.
Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy
Transl. Oncol.
3
43-49
2010
Homo sapiens
brenda
Muzaffar, S.; Shukla, N.; Massey, Y.; Angelini, G.D.; Jeremy, J.Y.
NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: inhibition with iloprost
Eur. J. Pharmacol.
658
187-192
2011
Homo sapiens
brenda
Chao, W.C.; Lu, J.F.; Wang, J.S.; Yang, H.C.; Pan, T.A.; Chou, S.C.; Wang, L.H.; Chou, P.T.
Probing ligand binding to thromboxane synthase
Biochemistry
52
1113-1121
2013
Homo sapiens
brenda
Das, A.; Varma, S.S.; Mularczyk, C.; Meling, D.D.
Functional investigations of thromboxane synthase (CYP5A1) in lipid bilayers of nanodiscs
ChemBioChem
15
892-899
2014
Homo sapiens
brenda
Cathcart, M.C.; Gately, K.; Cummins, R.; Kay, E.; OByrne, K.J.; Pidgeon, G.P.
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer
Mol. Cancer
10
25
2011
Homo sapiens
brenda
Sathler, P.; Santana, M.; Loureno, A.; Rodrigues, C.; Abreu, P.; Cabral, L.; Castro, H.
Human thromboxane synthase Comparative modeling and docking evaluation with the competitive inhibitors dazoxiben and ozagrel
J. Enzyme Inhib. Med. Chem.
29
527-531
2014
Homo sapiens
brenda
5.3.99.5 thromboxane-A synthase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
